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The prevalence of smoking has consistently
been stated to be higher in drug-dependent pa-
tients than in the general population. For example,
cigarette smoking rates among the general popu-
lation are reported to be some 25% in the USA [1]
and 30–40% in Switzerland [2, 3]. Rates among
abusers of illicit substances in treatment pro-
grammes are reported to be more than 70% [4–9]. 
Various factors may account for dependence
on different substances, and there is a growing
body of data to explain the extent to which nico-
tine and other substances share similar brain path-
ways [10–12].
The pattern of tobacco use has been shown to
be a good predictor for abuse of other psycho-
active drugs [7, 13]: individuals who have never
smoked cigarettes rarely use illicit drugs; the heav-
ier the cigarette smoking, the greater the likeli-
hood that alcohol, marijuana, and/or cocaine will
be used [14, 15]. In experimental settings subjects
have been observed to smoke more cigarettes after
consuming single doses of amphetamine, ethanol,
heroin, methadone and pentobarbital than after
consuming placebos [14]. Smoking habits of pa-
tients with substance abuse disorders also suggest
that they are more physically dependent on nico-
tine than the average smoker [16]. Drug-depend-
ent smokers have, furthermore, been reported to
have lower smoking cessation rates [17]. On the
other hand, efforts to stop smoking have been
shown not to impair chemical dependency treat-
ment outcomes, but may be associated with im-
proved chemical dependency treatment outcomes
[7, 18–20]. 
Despite the high smoking rates and the heavy
burden of tobacco-related problems, little effort
has been directed toward reducing the prevalence
of smoking in these patients. Drug treatment pro-
fessionals may often be reluctant to address to-
bacco dependence in their patients [7, 18, 21]. The
fear that attempts at smoking cessation would be
stressful and jeopardise drug treatment outcomes
is one reason often mentioned. Other reasons are
staff smoking practices, the fear that programmes
may lose clients if treatment for tobacco depend-
ence is included, a sense that smoking is a less im-
portant problem than other drugs, and, finally, tra-
dition. In many cases also, harmful consequences
of other addictive disorders may be more immedi-
ately apparent than for tobacco. Hence smoking in
drug dependent patients may frequently be de-
fined as a minor problem.
North American surveys have shown that up
to 70% of recovering drug dependent patients may
be interested in receiving smoking cessation coun-
selling or treatment [6, 7, 22]. Although their ces-
Nicotine cessation programmes in Switzer-
land, which are commonly based on the stage of
change model of Prochaska and DiClemente
(1983), are rarely offered to patients with illicit
drug dependence. This stands in contrast to the
high smoking rates and the heavy burden of to-
bacco-related problems in these patients.
The stage of change was therefore assessed by
self-administered questionnaire in 100 inpatients
attending an illegal drug withdrawal programme.
Only 15% of the patients were in the contempla-
tion or decision stage. 93% considered smoking
cessation to be difficult or very difficult. These data
show a discrepancy between the motivation to
change illegal drug consumption habits and the
motivation for smoking cessation. The high pro-
portion of patients remaining in the precontem-
plation stage for smoking cessation, in spite of their
motivation for illicit drug detoxification, may be
due to the perception that cessation of smoking is
more difficult than illicit drug abuse cessation.
Key words: substance abuse; smoking; smoking ces-
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sation rate may be lower than in non-opiate de-
pendent smokers, they can successfully stop smok-
ing [17, 22–24]. 
Effective nicotine addiction treatments are in-
creasingly modelled to the specific smoking pat-
terns as well as quitting motives and barriers in
smokers in identified high-risk groups [20]. These
are largely based on the stage of change model of
Prochaska and DiClemente [25]. One implication
of this model is that individuals will be most re-
ceptive to interventions tailored to their particular
stage of change. Precontemplators may be more
responsive to motivational programmes designed
to move them into the contemplation stage, and
not respond to “action” strategies geared to im-
mediate cessation. Determining motivational
stage is therefore critical for the design of smok-
ing cessation programmes for drug dependent pa-
tients.
Whereas a general trend towards smoking ces-
sation can also be observed in Switzerland [26],
smoking cessation is rarely addressed in drug de-
pendent patients. The objective of the present
study was to assess the stage of change for tobacco
consumption in illicit drug dependent patients at-
tending a specialised ward for drug detoxification. 
Methods
Subjects were 100 consecutively admitted smoking
patients voluntarily attending a drug withdrawal pro-
gramme at the University Psychiatric Hospital in Lau-
sanne. To attain the target sample of 100 smoking patients
102 patients entering the programme had to be screened,
2 patients being non-smokers. The time span for recruit-
ment of the sample was 7 months. The prerequisites for
hospitalisation in the unit are, among others, referral by a
professional (physician, social worker etc.), a prehospital-
isation consultation and a rehabilitative programme
planned directly after hospitalisation in the unit. Local
health policy regulations rule out coercion of addicts on
inpatient withdrawal treatment, and hence all patients
were admitted on a completely voluntary basis. The stan-
dard hospitalisation duration planned is 10 days for heroin
and 14 days for methadone detoxification. The standard
approach is motivational interviewing, a directive, client-
centred counselling style for eliciting behaviour change by
helping clients to explore and resolve ambivalence [27].
Inclusion criteria were dependence on opiates or cocaine
(ICD-10 criteria) and sufficient knowledge of French to
read and understand the questionnaire instructions and
give informed consent.
After giving informed consent all patients filled in a
self-administered schedule on the first day of hospitalisa-
tion, including sociodemographic data, data on smoking
and drug abuse history, the Fagerström test for nicotine
dependence (FTND) [28, 29] and a stage of change algo-
rithm [30]. The FTND is a commonly used paper-and-
pencil measure of tobacco dependence for smokers. It is a
self-administered 6-item questionnaire which can be
completed within 2–3 minutes and yields a score between
0 and 10. There is no standard cut-off for the presence or
absence of nicotine dependence; one suggested scoring
system is 1 to 2 indicates very low dependence, 3 to 4 low
dependence, 5 medium dependence, 6 to 7 high depend-
ence, and 8 to 10 very high dependence. Smokers who
were seriously thinking of stopping within the next 6
months were defined as “contemplators”, while those who
were not considering stopping were defined as “precon-
templators”. Patients planning smoking cessation within
the following 30 days were considered to be in the “prepa-
ration” stage. The relapse stage was defined as being an
actual smoker and having made at least one withdrawal at-
tempt of at least 24 hours during the last 12 months. Ex-
smokers were defined as being in the maintenance stage.
Tests of statistical significance were carried out with
chi-square tests where appropriate, using the statistical
package SPSS version 10.1 for Windows. Statistical sig-
nificance was defined at the .05 level.
Results
Characteristics of the sample
A total of 77 (75.5%) men and 25 (24.5%)
women (mean age: 31.0 years SD: 6.6 years; range:
20–50 years) were included in the study. Of these,
n %
Drug consumed Opiates 96 94.1
Cocaine 47 46.1
Benzodiazepines 58 56.9
Alcohol (dependence) 13 12.7
Cannabis 65 63.7
Number of drugs 1 13 12.7
consumed 2 26 25.5
3 39 38.2
4 23 22.5
5 1 1.0
Table 1
Drug consumption of
the study sample
over the last week.
74 (72.5%) were attending the clinic for the first
time. The remaining 28 (27.5%) had been hospi-
talised before. 
The sample’s drug consumption is given in
table 1. 
Smoking habits
The mean duration of tobacco consumption
was 14.9 (SD: 7.0; range 2–38) years. Reported dif-
ficulty in stopping tobacco consumption, the dis-
tribution with regard to the number of daily ciga-
rettes, the degree of nicotine dependence as mea-
sured by the Fagerström scale and the stage of
change distribution are given in table 2. The mean
Fagerström score was 4.66 (SD 1.14).
To estimate associations between sex, age, or-
dinal of hospitalisation on the one hand and stage
of change on the other, the variables were cross-
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tabulated and chi-square scores computed. No sta-
tistically significant interdependence was found
(data not shown).
Discussion
Most drug dependent patients attending the
inpatient detoxification programme of the Uni-
versity Psychiatric Hospital in Lausanne, Switzer-
land, were in the precontemplation stage with re-
gard to tobacco consumption. This contrasts with
a previous survey on alcohol dependent patients
entering the alcohol inpatient detoxification pro-
gramme of the University of Lausanne [31], where
42.3% were classified as precontemplators and
46.5% as contemplators. Relative figures for the
general Swiss population have recently been pub-
lished by Etter et al. [32]. In 1995–1996 they per-
formed two mailed surveys in a representative sam-
ple of 742 residents of Geneva and in a represen-
tative sample of 2,270 university members. They
found 74% of the smokers in the Geneva popula-
tion sample to be in the precontemplation stage,
22% in contemplation, and 4% in preparation. In
the university sample the corresponding figures
were 72, 20, and 8%.
The high proportion of patients remaining in
the precontemplation stage for smoking cessation,
in spite of their motivation for drug detoxification,
may be due to the perception of nicotine as a more
difficult drug to withdraw. This was also found in
our sample, as 93% of the patients considered
smoking cessation difficult or very difficult. Fur-
thermore, the patients often consider smoking a
minor problem compared to their illegal drug con-
sumption, an attitude which is regularly shared by
addiction treatment professionals. One further im-
portant possible quitting barrier may be staff who
smoke, as they will be less likely to urge cessation
[21]. As some nurses in our facility were smokers
and smoking was only partly restricted on the ward
at the time of the study, this may have biased the
data toward precontemplation.
Whereas Swiss drug dependent patients may
have only limited interest in smoking cessation, ad-
dressing tobacco consumption should nevertheless
be a main concern in view of the high associated
morbidity and mortality. The utility of tobacco
counselling and non-smoking policies has been
shown for several North American drug treatment
facilities [19, 24, 33]. Smoke-free hospital policies
for inpatient substance abuse disorder treatment
programmes have, furthermore, been shown to be
feasible and well accepted by patients and staff, and
not to jeopardise alcohol treatment outcomes [21,
34].
There are limitations to the present study
which may lessen the generalisability of the results.
Patients were recruited from only one centre,
which is located in the metropolitan area of the
French-speaking town of Lausanne. Attitudes in
the French-speaking part of Switzerland are usu-
ally considered to be more permissive with regard
to legal drugs and smoking, but more prohibitive
n %
Difficulty smoking Very easy 0 0.0
cessation Easy 7 7.0
Difficult 46 46.0
Very difficult 47 47.0
Number of cigarettes 0–10 9 9.0
per day 11–20 49 49.0
21–30 32 32.0
>30 10 10.0
Fagerström score 1 0 0.0
2 3 3.0
3 10 10.0
4 33 33.0
5 31 31.0
6 19 19.0
7 3 3.0
8 1 1.0
9 0 0
Stage of change Precontemplation 75 73.5
Contemplation 8 7.8
Decision 8 7.8
Maintenance 2 2.0
Relapse 9 8.8
Table 2 
Smoking habits.
S W I S S  M E D  W K LY 2 0 0 4 ; 1 3 4 : 3 2 2 – 3 2 5 ·  w w w. s m w. c h 325
with regard to illegal substances. Hence it is not
impossible that interest in smoking cessation
would be higher in German-speaking drug de-
pendent patients. Recruitment was moreover lim-
ited to patients attending a high threshold in-
patient facility, i.e. patients with a supposed high
motivation to change their illegal drug consump-
tion habits. Patients in low threshold programmes
such methadone substitution may differ from our
sample.
In conclusion, the present survey shows a dis-
crepancy between the motivation to change illegal
drug consumption habits and the motivation to
stop smoking. Designing smoking cessation pro-
grammes for this population should take into ac-
count these patients’ low level of motivation and
be especially aimed at strengthening self-efficacy
and quitting motivation. As minimal-contact quit
smoking strategies have shown their feasibility and
efficacy in reducing tobacco consumption not only
in community populations but also in addicted pa-
tients [35], they can be introduced into drug de-
pendency programmes without incurring major
cost. 
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